Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


09.10.2017

1 Am J Hematol
3 Blood
2 Bone Marrow Transplant
1 Eur J Haematol
2 Haematologica
1 Hum Pathol
1 J Clin Oncol
3 Lancet Oncol
2 Leuk Lymphoma
2 Mod Pathol
2 N Engl J Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. AKHTAR S, Montoto S, Boumendil A, Finel H, et al
    High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation (EBMT)-Lymphoma Working Party.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24927.
    PubMed     Text format     Abstract available


    Blood

  2. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Text format     Abstract available

  3. BALAKRISHNA JP, Jaffe ES
    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.
    PubMed     Text format    

  4. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  5. RIEDELL PA, Bishop MR
    Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available

  6. GALIENI P, Troiani E, Bigazzi C, Mazzotta S, et al
    Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    Eur J Haematol

  7. ELORANTA S, Branvall E, Celsing F, Papworth K, et al
    Increasing incidence of Primary CNS lymphoma but no improvement in survival in Sweden 2000-2013.
    Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12980.
    PubMed     Text format     Abstract available


    Haematologica

  8. LANDMANN E, Burkhardt B, Zimmermann M, Meyer U, et al
    Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.
    Haematologica. 2017 Oct 5. pii: haematol.2015.139162.
    PubMed     Text format     Abstract available

  9. YOUNES A, Salles G, Martinelli G, Bociek RG, et al
    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.
    Haematologica. 2017 Sep 29. pii: haematol.2017.169656.
    PubMed     Text format     Abstract available


    Hum Pathol

  10. ZHANG S, Bayerl MG
    Florid splenic gamma/delta T-cell proliferation in patients with splenomegaly and cytopenias: a "high stakes" diagnostic challenge.
    Hum Pathol. 2017;66:216-221.
    PubMed     Text format     Abstract available


    J Clin Oncol

  11. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2017 Oct 4:JCO2017754648. doi: 10.1200/JCO.2017.75.4648.
    PubMed     Text format     Abstract available


    Lancet Oncol

  12. GANESAN AP, Jiang W, Kuo DJ, Bhattacharjee R, et al
    Obstructive sleep apnoea as a presenting manifestation of non-Hodgkin lymphoma in a child.
    Lancet Oncol. 2017;18:e618.
    PubMed     Text format    

  13. TANIMOTO T, Oshima K, Tsuda K, Mori J, et al
    Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma.
    Lancet Oncol. 2017;18:e557.
    PubMed     Text format    

  14. CHIAPPELLA A, Martelli M, Evangelista A, Vitolo U, et al
    Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply.
    Lancet Oncol. 2017;18:e558.
    PubMed     Text format    


    Leuk Lymphoma

  15. SU C, Nguyen KA, Bai HX, Balaji D, et al
    Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
    Leuk Lymphoma. 2017 Oct 5:1-7. doi: 10.1080/10428194.2017.1379078.
    PubMed     Text format     Abstract available

  16. JACHIET V, Mekinian A, Carrat F, Grignano E, et al
    Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.
    Leuk Lymphoma. 2017 Oct 3:1-7. doi: 10.1080/10428194.2017.1379075.
    PubMed     Text format     Abstract available


    Mod Pathol

  17. MIYAOKA M, Kikuti YY, Carreras J, Ikoma H, et al
    Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

  18. HU Z, Sun Y, Schlette EJ, Tang G, et al
    CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  19. MARCUS R, Davies A, Ando K, Klapper W, et al
    Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    N Engl J Med. 2017;377:1331-1344.
    PubMed     Text format     Abstract available

  20. ARMITAGE JO, Longo DL
    Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
    N Engl J Med. 2017;377:1389-1390.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: